Analyst consensus rating
Bioventus Analyst Rating: none
Direct answer
Bioventus's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.60.
Forecast evidence checked October 27, 2026.
Get free Bioventus email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.42
- Average price target
- $17.60
- High price target
- $19.00
- Low price target
- $15.00
- Low target gap
- +4%
- Target upside
- +22.1%
- High target gap
- +31.8%
- Target range width
- 27.7%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bioventus?
Bioventus has a verified none consensus. The same dataset has an average price target of $17.60.
How far are Bioventus's low and high targets from the recorded price?
The low target implies +4%, while the high target implies +31.8%.
How many analysts are included in Bioventus's consensus?
The verified consensus includes 5 analysts.
How is Bioventus's target upside or downside calculated?
The average target of $17.60 is divided by the recorded price of $14.42, then one is subtracted to produce +22.1%. This does not guarantee a future return.
When was Bioventus's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.